PubRank

Toshimi Takano

Author PubWeight™ 19.78‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 2006 1.36
2 Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res 2008 1.31
3 Treatment of acute promyelocytic leukemia. N Engl J Med 2013 1.14
4 Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Clin Cancer Res 2007 0.99
5 Resistance to androgen-pathway drugs in prostate cancer. N Engl J Med 2014 0.93
6 Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. Cancer Sci 2008 0.93
7 Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 2015 0.92
8 Treatment of lung cancer. N Engl J Med 2009 0.84
9 Cabazitaxel for castration-resistant prostate cancer. Lancet 2011 0.84
10 Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype. BMC Cancer 2014 0.82
11 Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment. Cancer Sci 2009 0.79
12 Erlotinib in lung cancer. N Engl J Med 2005 0.78
13 Can epidermal growth factor receptor-fluorescent in situ hybridization predict clinical benefit from cetuximab treatment in patients with non-small-cell lung cancer? J Clin Oncol 2008 0.76
14 The safety of chemotherapy for breast cancer patients with hepatitis C virus infection. J Cancer 2013 0.76
15 Olaparib in platinum-sensitive ovarian cancer. N Engl J Med 2012 0.76
16 Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. J Cancer Res Clin Oncol 2012 0.76
17 Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2012 0.75
18 Early prostate cancer--treat or watch? N Engl J Med 2011 0.75
19 Exemestane for breast-cancer prevention. N Engl J Med 2011 0.75
20 Neoadjuvant chemotherapy or primary surgery in advanced ovarian cancer. N Engl J Med 2010 0.75
21 Colorectal-cancer screening. N Engl J Med 2012 0.75
22 The safety of chemotherapy for colorectal cancer patients with hepatitis C virus infection. Med Oncol 2014 0.75
23 Radiation-induced esophagitis exacerbated by everolimus. Case Rep Oncol 2013 0.75
24 Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients. Int J Clin Oncol 2015 0.75
25 [Heart failure]. Nihon Rinsho 2015 0.75
26 Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. Int J Clin Oncol 2015 0.75
27 Reduction of toxicity by reversing the order of infusion of docetaxel and cyclophosphamide. Chemotherapy 2013 0.75
28 The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer. Jpn J Clin Oncol 2013 0.75